EdgarLookup

Atlassian Corp — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Atlassian Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-4.9%
Profit Margin
Net income ÷ revenue
-4.2%
Return on Assets
Net income ÷ assets
3.49x
Debt-to-Equity
Total liabilities ÷ equity
+19.7%
Revenue Growth
Year over year

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $5.22B Aug 15, 2025
FY2025 Jun 30, 2024 $4.36B Aug 15, 2025
FY2025 Jun 30, 2023 $3.53B Aug 15, 2025
FY2024 Jun 30, 2022 $2.80B Aug 16, 2024
FY2023 Jun 30, 2021 $2.09B Aug 18, 2023

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $4.32B Aug 15, 2025
FY2025 Jun 30, 2024 $3.56B Aug 15, 2025
FY2025 Jun 30, 2023 $2.90B Aug 15, 2025
FY2024 Jun 30, 2022 $2.35B Aug 16, 2024
FY2023 Jun 30, 2021 $1.76B Aug 18, 2023

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 ($256.69M) Aug 15, 2025
FY2025 Jun 30, 2024 ($300.52M) Aug 15, 2025
FY2025 Jun 30, 2023 ($486.76M) Aug 15, 2025
FY2024 Jun 30, 2022 ($519.51M) Aug 16, 2024
FY2023 Jun 30, 2021 ($578.98M) Aug 18, 2023

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 ($130.39M) Aug 15, 2025
FY2025 Jun 30, 2024 ($117.08M) Aug 15, 2025
FY2025 Jun 30, 2023 ($345.22M) Aug 15, 2025
FY2024 Jun 30, 2022 $70.08M Aug 16, 2024
FY2023 Jun 30, 2021 $141.41M Aug 18, 2023

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $2.67B Aug 15, 2025
FY2025 Jun 30, 2024 $2.18B Aug 15, 2025
FY2025 Jun 30, 2023 $1.87B Aug 15, 2025
FY2024 Jun 30, 2022 $1.29B Aug 16, 2024
FY2023 Jun 30, 2021 $932.99M Aug 18, 2023

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $1.46B Aug 15, 2025
FY2025 Jun 30, 2024 $1.45B Aug 15, 2025
FY2025 Jun 30, 2023 $868.11M Aug 15, 2025
FY2024 Jun 30, 2022 $821.04M Aug 16, 2024
FY2023 Jun 30, 2021 $789.96M Aug 18, 2023

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $44.85M Aug 15, 2025
FY2025 Jun 30, 2024 $33.11M Aug 15, 2025
FY2025 Jun 30, 2023 $25.81M Aug 15, 2025
FY2024 Jun 30, 2022 $70.58M Aug 16, 2024
FY2023 Jun 30, 2021 $31.52M Aug 18, 2023

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $6.04B Aug 15, 2025
FY2025 Jun 30, 2024 $5.21B Aug 15, 2025
FY2024 Jun 30, 2023 $4.11B Aug 16, 2024
FY2023 Jun 30, 2022 $3.33B Aug 18, 2023

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $4.70B Aug 15, 2025
FY2025 Jun 30, 2024 $4.18B Aug 15, 2025
FY2024 Jun 30, 2023 $3.45B Aug 16, 2024
FY2023 Jun 30, 2022 $3.00B Aug 18, 2023

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $1.35B Aug 15, 2025
FY2025 Jun 30, 2024 $1.03B Aug 15, 2025
FY2025 Jun 30, 2023 $654.67M Aug 15, 2025
FY2025 Jun 30, 2022 $327.37M Aug 15, 2025
FY2024 Jun 30, 2021 $313.26M Aug 16, 2024
FY2023 Jun 30, 2020 $566.64M Aug 18, 2023

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $1.30B Aug 15, 2025
FY2025 Jun 30, 2024 $1.29B Aug 15, 2025
FY2025 Jun 30, 2023 $727.21M Aug 15, 2025
FY2024 Jun 30, 2022 $722.84M Aug 16, 2024
FY2023 Jun 30, 2021 $715.93M Aug 18, 2023

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 ($4.24B) Aug 15, 2025
FY2025 Jun 30, 2024 ($3.20B) Aug 15, 2025
FY2024 Jun 30, 2023 ($2.51B) Aug 16, 2024
FY2023 Jun 30, 2022 ($1.87B) Aug 18, 2023

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 $2.51B Aug 15, 2025
FY2025 Jun 30, 2024 $2.18B Aug 15, 2025
FY2025 Jun 30, 2023 $2.10B Aug 15, 2025
FY2024 Jun 30, 2022 $1.39B Aug 16, 2024
FY2023 Jun 30, 2021 $919.23M Aug 18, 2023

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 0 Aug 15, 2025
FY2025 Jun 30, 2024 (1) Aug 15, 2025
FY2025 Jun 30, 2023 (1) Aug 15, 2025
FY2024 Jun 30, 2022 (2) Aug 16, 2024
FY2023 Jun 30, 2021 (2) Aug 18, 2023

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Jun 30, 2025 0 Aug 15, 2025
FY2025 Jun 30, 2024 (1) Aug 15, 2025
FY2025 Jun 30, 2023 (1) Aug 15, 2025
FY2024 Jun 30, 2022 (2) Aug 16, 2024
FY2023 Jun 30, 2021 (2) Aug 18, 2023